Keywords
heart transplantation - heart valve surgery - minimally invasive surgery; includes
port access minithoracotomy - reoperation
Introduction
Fifty years after the first heart transplantation (HTX), posttransplant survival is
continuously improving. The mean survival in adult patients is 10.7 years; pediatric
patients present a mean survival of 16.1 years. Main causes of death remain primary
graft failure, infections, and multiorgan failure.[1] With better survival rates, the incidences of cardiac pathologies such as cardiac
allograft vasculopathy and valvular diseases will occur more often.
We report on a patient with mitral valve (MV) stenosis 10 years after successful HTX.
We performed an MV replacement due to severe atrioventricular valve degeneration through
a minimally invasive approach through right thoracotomy.
Case Report
A 50-year-old female presented with progressive heart failure due to obstruction of
the MV after an uneventful HTX for dilative cardiomyopathy in October 2008. Initial
postoperative echocardiography showed normal pump function and no signs of rejection.
Standard immunosuppression regime consisted of a combination of prednisone, mycophenolate,
and tacrolimus. However, due to persistent diarrhea, mycophenolic acid was changed
in benefit of everolimus in 2009. Since 2010, the patient has been under immunosuppressive
treatment with tacrolimus and azathioprine.
In 2012, doming of the MV with mild stenosis was detected. An elective balloon valvuloplasty
procedure for MV stenosis in 2018 (valve orifice area of 1.3 cm2, peak pressure gradient [PPG] 24 of mm Hg, mean pressure gradient (MPG) of 14 mm
Hg) was unsuccessful. The patient was admitted for surgical valve replacement and
deobstruction of the left ventricular outflow tract (LVOT) (PPG of 35 mm HG, MPG of
19 mm Hg) ([Fig. 1]).
Fig. 1 Intraoperative transoesophageal echocardiography of a subvalvular membrane in the
left ventricular outflow tract (marked by an arrow), measuring 1.0 × 0.5 cm, with
probable connection to the anterior mitral valve leaflet.
Repeated coronary angiography showed a known LCX (left circumflex artery) stenosis
aggravated from 25% (since HTX) to 50 to 75%, and a percutaneous transluminal coronary
angioplasty was performed and two-drug eluting stents were placed.
Operative Technique
After sternotomy during HTX in 2008, we performed a right minithoracotomy with videoscopy
and cardiopulmonary bypass through peripheral right femoral cannulation. Transesophageal
echocardiography confirmed a subvalvular membrane in the LVOT, measuring 1.0 × 0.5 cm,
with probable connection to the anterior mitral leaflet ([Fig. 1]). Invasive PPG in the LVOT was 25 mm Hg.
The fifth intercostal space was opened through minimal skin incision in the submammary
crease. Through the occlusion catheter (IntraClude Intra-Aortic Occlusion Device,
Edwards Lifesciences Corporation), aortic cross-clamping, antegrade cardioplegia,
and aortic root venting were performed.[2] Cardiac arrest was established by 2-L Custodiol (Dr. Franz Köhler Chemie GmbH) after
inflation of the IntraClude balloon.
Incision of the left atrium was followed by excision of the MV and the subvalvular
membrane ([Fig. 2]). MV leaflets showed severe endocardial thickening. The subvalvular membrane of
the LVOT was identified and excised as well. Due to the rigidity of the endocardial
tissue, MV replacement with a biological prosthesis was agreed upon in accordance
with previous agreement of the patient. We implanted a 27-mm Hancock II MV prosthesis
(Medtronic).
Fig. 2 Excision of the subvalvular membrane through the left atrium (filmed by videoscopy).
Aortic cross-clamp time was 81 minutes, and overall CBP time was 145 minutes.
Postoperative Course
After 1 day in intensive care unit and 5 days in the intermediate care ward, the patient
was discharged on postoperative day 10.
Histological work-up showed hyaline and myxomatous degeneration with calciferous parts.
There were no signs of previous endocarditis.
Discussion
Cases of MV dysfunction after HTX are rare. There are only a few studies and case
reports that mention MV repair, mainly due to MV regurgitation. In a retrospective
study, Goekler et al first described MV replacement for stenosis after hemodialysis
for 2 years following HTX.[3] Our case reports the first study published on minimally invasive MV replacement
for valve stenosis with intraluminal aortic clamping. Despite worldwide long experience
in the field of HTX, numbers of secondary surgical interventions in HTX recipients
are scarce. Overall prevalence of reoperations after successful HTX is estimated to
be between 2 and 5%. Even high-volume centers describe only a small number of reoperations.[3]
[4]
[5]
Considering the high possibility of adhesions from preceding HTX, the hazard of traumatic
or iatrogenic injuries can be reduced by avoiding resternotomy. After aortic and pulmonary
artery anastomosis during HTX, the chances for severe adhesions are more relevant.
In our opinion, intraluminal aortic clamping via a three-lumen catheter to circumvent
severe adhesions between the aorta and the pulmonary artery after great vessel anastomosis
during HTX is a safe option. Main complications using intraluminal clamping are described
as aortic dissection, iliac artery injury, and cerebrovascular events. Nevertheless,
minimally invasive valve surgery is considered being a safe and effective method in
short- and long-term results, especially in redo operations.[6]
In a large retrospective study, Pasca et al showed that renal insufficiency is a risk
factor for degenerative mitral stenosis.[7] In patients suffering from MV calcification, kidney disease is more common in patients
younger than 50 years.[8] We consider the renal insufficiency of our patient due to immunosuppression therapy
as the main cause for the aggravation of MV degeneration over a time period of 10
years.
This case was discussed in our multidisciplinary team of cardiac surgeons and cardiologists
before indication for reoperation was decided upon after conventional catheter approach
was unsuccessful.
Conclusion
We report the first case of successful MV replacement in an HTX recipient through
minimally invasive right thoracotomy using aortic endoclamp. Considering the lack
of international recommendations and guidelines for this specific patient cohort,
we emphasize the multidisciplinary approach in treating these patients who need secondary
cardiac interventions after HTX.
